Manageability of acute severe heart failure complicated with left ventricular thrombosis during therapy for breast cancer

International Heart Journal

Volumn 51, Issue 2, 2010, Pages 141-145

  Szmit, Sebastian ^a,c   Kurzyna, Marcin ^b   Główczyńska, Renata ^a   Grabowski, Marcin ^a   Kober, Jarosław ^b   Czerniawska, Justyna ^b   Filipiak, Krzysztof J ^a   Opolski, Grzegorz ^a   Szczylik, Cezary ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^c MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Acute heart failure; Anthracycline; Early breast cancer; Trastuzumab; Ventricular thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTIBIOTIC AGENT; CARVEDILOL; CYCLOPHOSPHAMIDE; DIGOXIN; DOXORUBICIN; ENALAPRIL; ENOXAPARIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPARIN; SPIRONOLACTONE; TORASEMIDE; TRASTUZUMAB;

ADULT; ARTICLE; BLOOD CLOT; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPNEA; ECHOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE THROMBOSIS; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE FAILURE; HEART VENTRICLE THROMBOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LEG EDEMA; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PLEURA CAVITY; PLEURA FLUID; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; SYSTOLIC HEART FAILURE; THORAX RADIOGRAPHY; TUMOR VOLUME;

ADULT; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; THROMBOSIS;

EID: 77951486298     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.141     Document Type: Article

References (18)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Tras-tuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
3. AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients, http://www.abstracts2view.com/sabcs06/view.php?nu=SABCS06L_78.
4. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61: 14-21. (Review)
5. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
7. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900-2.
8. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.
9. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopatho-logic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
10. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
11. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
12. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
13. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26: 1231-8.
14. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregu-lin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007; 116: 954-60. (Review)
15. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overex-pressing breast cancer: current experience and future strategies. Ann Oncol 2008; 19: 1530-9.
16. Jones AL, Verrill M, Barrett-Lee P, et al. Development and implementation of new UK National Cancer Research Institute (NCRI) guidelines for preventing and managing cardiac events with trastuzumab. Ann Oncol 2008; 19: viii85.
17. Mackey JR, Clemons M, Cote MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008; 15: 24-35.
18. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25: 512.